Umoja Biopharma Presents Preclinical Data at the 65th American Society of Hematology Annual Meeting Demonstrating In Vivo CAR T Cell Generation with Potent and Highly Durable Activity
11 déc. 2023 13h30 HE
|
Umoja Biopharma, Inc.
Durable B cell aplasia up to 76 days observed in non-human primates following a single dose of VivoVec™ particles without lymphodepletion, exceeding industry benchmarks for ex vivo CAR T cell...
Umoja Biopharma Announces Oral Presentation at the 65th American Society of Hematology Annual Meeting
02 nov. 2023 09h43 HE
|
Umoja Biopharma, Inc.
SEATTLE, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc., a transformative immuno-oncology company creating off-the-shelf treatments for solid and hematologic cancers, today announced that...
Umoja Biopharma Announces Opening of Development and Manufacturing Facility in Louisville, Colorado
19 oct. 2023 10h00 HE
|
Umoja Biopharma, Inc.
SEATTLE, Oct. 19, 2023 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc., a transformative immuno-oncology company creating off-the-shelf treatments for solid and hematologic cancers, announced today the...
Umoja Biopharma to Present at the 2023 Cell & Gene Meeting on the Mesa
05 oct. 2023 14h30 HE
|
Umoja Biopharma, Inc.
SEATTLE, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc., a transformative immuno-oncology company creating off-the-shelf treatments for solid and hematologic cancers, today announced that...
Umoja Biopharma’s VivoVec Platform Presents Encouraging Proof-of-Concept Data in Ongoing Non-Human Primate Study at the 8th CAR-TCR Summit
01 sept. 2023 12h30 HE
|
Umoja Biopharma, Inc.
Preliminary data from ongoing preclinical study include rapid, durable chimeric antigen receptor (CAR) T cell generation in vivo after a single infusion of VivoVec particles Additional data to be...
Umoja Biopharma to Unveil Preliminary Positive Non-Human Primate Data for the First Time at the 8th CAR-TCR Summit
23 août 2023 10h00 HE
|
Umoja Biopharma, Inc.
SEATTLE, Aug. 23, 2023 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc., a transformative immuno-oncology company creating off-the-shelf treatments for cancers, today announced it will unveil preliminary...
Umoja Biopharma to Present at the 2023 BIO International Convention
31 mai 2023 10h17 HE
|
Umoja Biopharma, Inc.
SEATTLE, May 31, 2023 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc., a transformative immuno-oncology company creating off-the-shelf treatments for solid and hematological cancers, today announced that...
Umoja Biopharma Presents New Preclinical Data at the American Society of Gene and Cell Therapy 26th Annual Meeting Demonstrating Potent In Vivo CAR T Cell Generation and Durable Anti-Tumor Activity
17 mai 2023 09h00 HE
|
Umoja Biopharma, Inc.
UB-VV200 preclinical data highlight successful generation of TagCAR T cells, which demonstrate dose-dependent anti-tumor activity when used in combination with TumorTag™ technology in an in vivo model...
Umoja Biopharma to Present New Data at the American Society of Gene and Cell Therapy 26th Annual Meeting
03 mai 2023 08h00 HE
|
Umoja Biopharma, Inc.
SEATTLE, May 03, 2023 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc., an immuno-oncology company pioneering off-the-shelf, integrated therapeutics that reprogram immune cells to treat patients with solid...
Umoja Biopharma to Present at the 41st Annual J.P. Morgan Healthcare Conference
04 janv. 2023 10h00 HE
|
Umoja Biopharma, Inc.
SEATTLE, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc., an immuno-oncology company pioneering off-the-shelf, integrated therapeutics that reprogram immune cells to treat patients with...